cardiovascular-agents and Parkinsonian-Disorders

cardiovascular-agents has been researched along with Parkinsonian-Disorders* in 23 studies

Other Studies

23 other study(ies) available for cardiovascular-agents and Parkinsonian-Disorders

Article	Year
Decreased HCN2 expression in STN contributes to abnormal high-voltage spindles in the cortex and globus pallidus of freely moving rats. Brain research, 2015, Aug-27, Volume: 1618 Abnormal oscillation in the cortical-basal ganglia loop is involved in the pathophysiology of parkinsonism. High-voltage spindles (HVSs), one of the main type abnormal oscillations in Parkinson's disease, are regulated by dopamine D2-like receptors but not D1-like receptors. However, little is known about how dopamine D2-like receptors regulate HVSs and the role of hyperpolarization-activated cyclic nucleotide-gated2 (HCN2) in HVSs regulation. We simultaneously recorded the local field potential (LFP) in globus pallidus (GP) and electrocorticogram (ECoG) in primary motor cortex (M1) in freely moving 6-hydroxydopamine (6-OHDA) lesioned or control rats. The expression of HCN2 and dopamine D2 receptor in the subthalamic nucleus (STN) was examined by immunochemical staining and Western blotting. We also tested the role of HCN2 in HVSs regulation by using pharmacological and shRNA methodology. We found that dopamine D2-like receptor agonists suppressed the increased HVSs in 6-OHDA lesioned rats. HCN2 was co-expressed with dopamine D2 receptor in the STN, and dopamine depletion decreased the expression of HCN2 as well as dopamine D2 receptor which contribute to the regulation of HVSs. HCN2 was down regulated by HCN2 shRNA, which thereby led to an increase in the HVSs in naïve rats while HCN2 agonist reduced the HVSs in 6-OHDA lesioned rats. These results suggest that HCN2 in the STN is involved in abnormal oscillation regulation between M1 cortex and GP. Topics: Animals; Antiparkinson Agents; Cardiovascular Agents; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Excitatory Amino Acid Antagonists; Globus Pallidus; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Indoles; Kynurenic Acid; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Subthalamic Nucleus; Wakefulness	2015
[CLINICAL ASPECTS OF MUSCLE RELAXANTS]. [Sogo rinsho] Clinic all-round, 1963, Volume: 12 Topics: Cardiovascular Agents; Chemical Phenomena; Chemistry; Muscle Relaxants, Central; Parkinsonian Disorders; Pharmacology	1963
The action of some derivatives of malonic and succinic acids on a Parkinson-type tremor. Medicina experimentalis : International journal of experimental medicine, 1961, Volume: 4 Topics: Antineoplastic Agents; Cardiovascular Agents; Heterocyclic Compounds; Malonates; Muscle Relaxants, Central; Parkinsonian Disorders; Succinates; Tremor	1961
[Cogentin, a medication with prolonged effect in parkinsonism]. Munchener medizinische Wochenschrift (1950), 1960, Apr-01, Volume: 102 Topics: Benztropine; Cardiovascular Agents; Muscle Relaxants, Central; Parkinsonian Disorders	1960
[Parkinzan therapy of patients with parkinsonism]. Sovetskaia meditsina, 1960, Volume: 24 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1960
[Experiences in the treatment of parkinsonism & other extrapyramidal disorders]. Die Medizinische, 1959, Feb-28, Volume: 4, Issue:9 Topics: Basal Ganglia Diseases; Cardiovascular Agents; Disease; Extrapyramidal Tracts; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
[Experiences with a new drug for control of parkinsonism, keithon]. Die Medizinische, 1959, Apr-11, Volume: 4, Issue:15 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
[Observations in treatment of parkinsonism with aturban]. Wiener medizinische Wochenschrift (1946), 1959, May-02, Volume: 109, Issue:18 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
[Medicinal treatment of parkinsonism]. Wiener medizinische Wochenschrift (1946), 1959, May-30, Volume: 109, Issue:22 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1959
Trial of a new remedy (Ciba 10870) in Parkinsonism. British medical journal, 1958, Apr-19, Volume: 1, Issue:5076 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
Treatment of Parkinsonism. British medical journal, 1958, Jun-28, Volume: 1, Issue:5086 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
[Cogentin, a new preparation for treatment of parkinsonism; preliminary report]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1958, Apr-01, Volume: 78, Issue:7 Topics: Benztropine; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
[Aturban (phenglutarimide), a new therapeutic drug for parkinsonism; comparative investigation on the therapy of parkinsonism]. Schweizerische medizinische Wochenschrift, 1958, Jul-26, Volume: 88, Issue:30 Topics: Cardiovascular Agents; Glutethimide; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1958
Parkinsonism: drug therapy; neurosurgical therapy. Postgraduate medicine, 1958, Volume: 24, Issue:6 Topics: Cardiovascular Agents; Humans; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Psychosurgery; Trihexyphenidyl	1958
[Keithon for therapy of parkinsonism]. Medizinische Monatsschrift, 1957, Volume: 11, Issue:12 Topics: Cardiovascular Agents; Diphenhydramine; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1957
Parkinsonism: treatment with curare. Annals of internal medicine, 1956, Volume: 45, Issue:5 Topics: Cardiovascular Agents; Curare; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Trihexyphenidyl	1956
[Therapeutic activity of a new drug, M.G. 1229, 4-(gamma-diethylaminopropyl)-hydroxydiphenylethane, in the parkinsonian syndrome]. Gazzetta medica italiana, 1956, Volume: 115, Issue:10 Topics: Cardiovascular Agents; Gamma Rays; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1956
[Benztropine methanesulfonate in the treatment of parkinsonism]. Prensa medica argentina, 1956, Dec-14, Volume: 43, Issue:50 Topics: Benztropine; Cardiovascular Agents; Mesylates; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1956
[Symptomatic therapeutic effect of cycrimine HCl in parkinsonian syndromes]. La Presse medicale, 1955, Mar-12, Volume: 63, Issue:19 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Piperidines	1955
[Treatment of parkinsonism with special reference to a new drug]. Jornal do medico, 1954, Nov-13, Volume: 25, Issue:616 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1954
The use of benzotropine sulfonate in the treatment of parkinsonism. The Medical annals of the District of Columbia, 1953, Volume: 22, Issue:5 Topics: Alkanesulfonates; Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders	1953
The treatment of parkinsonism with a new antispasmodic compound. Medical bulletin (Ann Arbor, Mich.), 1953, Volume: 19, Issue:3 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parasympatholytics; Parkinson Disease; Parkinsonian Disorders; Piperidines	1953
Evaluation of a new agent in the treatment of parkinsonism. Proceedings of the staff meetings. Mayo Clinic, 1953, Apr-08, Volume: 28, Issue:7 Topics: Cardiovascular Agents; Muscle Relaxants, Central; Parkinson Disease; Parkinsonian Disorders; Piperidines	1953